However, crizotinib is far from perfect as a first-line therapy for advanced ALK-positive NSCLC, because of its poor penetration of the central nervous system and the inevitable development of crizotinib resistance during therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.